Development of Hsp90 inhibitor to regulate cytokine storms in excessive delayed- and acute inflammation
•Excessive cytokine storms can be controlled through Hsp90.•Be01 has anti-inflammatory effects by decreasing surface molecules and cytokines in DCs and macrophages.•Inhibiting Hsp90 via Be01 highly decreased inflammation in vivo DTH and ALI models. The surplus cytokines remaining after use in the ea...
Gespeichert in:
Veröffentlicht in: | International immunopharmacology 2024-08, Vol.137, p.112470, Article 112470 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | |
---|---|
container_issue | |
container_start_page | 112470 |
container_title | International immunopharmacology |
container_volume | 137 |
creator | Sim, Hyun Bo Sang Son, Jun Gupta, Sunil K. Jeong, Seung-Hyun Choi, Yu-Jeong Han, Ji Yeon Ramos, Sonny C. Kim, Hyeongyeong Park, Dae-Han Yoo, Ho Jin Yoo, Young Joo Chang, Dong-Jo Mun, Seul-Ki Seo, Young Ho Kim, Jong-Jin |
description | •Excessive cytokine storms can be controlled through Hsp90.•Be01 has anti-inflammatory effects by decreasing surface molecules and cytokines in DCs and macrophages.•Inhibiting Hsp90 via Be01 highly decreased inflammation in vivo DTH and ALI models.
The surplus cytokines remaining after use in the early stages of the inflammatory response stimulate immune cells even after the response is over, causing a secondary inflammatory response and ultimately damaging the host, which is called a cytokine storm. Inhibiting heat shock protein 90 (Hsp90), which has recently been shown to play an important role in regulating inflammation in various cell types, may help control excessive inflammatory responses and cytokine storms.
We discovered an anti-inflammatory compound by measuring the inhibitory effect of CD86 expression on spleen DCs (sDCs) using the chemical compounds library of Hsp90 inhibitors. Subsequently, to select the hit compound, the production of cytokines and expression of surface molecules were measured on the bone marrow-derived DCs (BMDCs) and peritoneal macrophages. Then, we analyzed the response of antigen-specific Th1 cells. Finally, we confirmed the effect of the compound using acute lung injury (ALI) and delayed-type hypersensitivity (DTH) models.
We identified Be01 as the hit compound, which reduced CD86 expression the most in sDCs. Treatment with Be01 decreased the production of pro-inflammatory cytokines (IL-6, TNF-α, and IL-1β) in BMDC and peritoneal macrophages stimulated by LPS. Under the DTH model, Be01 treatment reduced ear swelling and pro-inflammatory cytokines in the spleen. Similarly, Be01 treatment in the ALI model decreased neutrophil infiltration and lower levels of secreted cytokines (IL-6, TNF-α).
Reduction of CD80 and CD86 expression on DCs by Be01 indicates reduced secondary inflammatory response by Th1 cells, and reduced release of pro-inflammatory cytokines by peritoneal macrophages may initially control the cytokine storm. |
doi_str_mv | 10.1016/j.intimp.2024.112470 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3071283250</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1567576924009913</els_id><sourcerecordid>3071283250</sourcerecordid><originalsourceid>FETCH-LOGICAL-c241t-a841bf906dff5f7660ad8c15afa44ca17dc379d8bca8db7c1cf9608bcf6197593</originalsourceid><addsrcrecordid>eNp9kE1PJCEQhsnGzarj_gNjOHrpEfoL-mJi_E5M9rKeCQ2Fy9gNLdCTnX8vk1aPniiop-oND0KnlKwpoe3FZm1dsuO0LklZrykta0Z-oCPKGS8oI81BrpuWFQ1ru0N0HOOGkPxe01_osOId4YQ3R-jlBrYw-GkEl7A3-CFOHcHW_bO9TT7g5HGAl3mQCbDaJf9qHeCYO2PMFIb_CmK0W8AaBrkDXWDpNJZqzrx1ZpDjKJP17gT9NHKI8PvjXKHnu9u_1w_F05_7x-urp0KVNU2F5DXtTUdabUxjWNsSqbmijTSyrpWkTKuKdZr3SnLdM0WV6VqSr6alHWu6aoXOl71T8G8zxCRGGxUMg3Tg5ygqwmjJq7IhGa0XVAUfYwAjpmBHGXaCErFXLDZiUSz2isWiOI-dfSTM_Qj6a-jTaQYuFwDyP7cWgojKglOgbQCVhPb2-4R3BDOQ0g</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3071283250</pqid></control><display><type>article</type><title>Development of Hsp90 inhibitor to regulate cytokine storms in excessive delayed- and acute inflammation</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>Sim, Hyun Bo ; Sang Son, Jun ; Gupta, Sunil K. ; Jeong, Seung-Hyun ; Choi, Yu-Jeong ; Han, Ji Yeon ; Ramos, Sonny C. ; Kim, Hyeongyeong ; Park, Dae-Han ; Yoo, Ho Jin ; Yoo, Young Joo ; Chang, Dong-Jo ; Mun, Seul-Ki ; Seo, Young Ho ; Kim, Jong-Jin</creator><creatorcontrib>Sim, Hyun Bo ; Sang Son, Jun ; Gupta, Sunil K. ; Jeong, Seung-Hyun ; Choi, Yu-Jeong ; Han, Ji Yeon ; Ramos, Sonny C. ; Kim, Hyeongyeong ; Park, Dae-Han ; Yoo, Ho Jin ; Yoo, Young Joo ; Chang, Dong-Jo ; Mun, Seul-Ki ; Seo, Young Ho ; Kim, Jong-Jin</creatorcontrib><description>•Excessive cytokine storms can be controlled through Hsp90.•Be01 has anti-inflammatory effects by decreasing surface molecules and cytokines in DCs and macrophages.•Inhibiting Hsp90 via Be01 highly decreased inflammation in vivo DTH and ALI models.
The surplus cytokines remaining after use in the early stages of the inflammatory response stimulate immune cells even after the response is over, causing a secondary inflammatory response and ultimately damaging the host, which is called a cytokine storm. Inhibiting heat shock protein 90 (Hsp90), which has recently been shown to play an important role in regulating inflammation in various cell types, may help control excessive inflammatory responses and cytokine storms.
We discovered an anti-inflammatory compound by measuring the inhibitory effect of CD86 expression on spleen DCs (sDCs) using the chemical compounds library of Hsp90 inhibitors. Subsequently, to select the hit compound, the production of cytokines and expression of surface molecules were measured on the bone marrow-derived DCs (BMDCs) and peritoneal macrophages. Then, we analyzed the response of antigen-specific Th1 cells. Finally, we confirmed the effect of the compound using acute lung injury (ALI) and delayed-type hypersensitivity (DTH) models.
We identified Be01 as the hit compound, which reduced CD86 expression the most in sDCs. Treatment with Be01 decreased the production of pro-inflammatory cytokines (IL-6, TNF-α, and IL-1β) in BMDC and peritoneal macrophages stimulated by LPS. Under the DTH model, Be01 treatment reduced ear swelling and pro-inflammatory cytokines in the spleen. Similarly, Be01 treatment in the ALI model decreased neutrophil infiltration and lower levels of secreted cytokines (IL-6, TNF-α).
Reduction of CD80 and CD86 expression on DCs by Be01 indicates reduced secondary inflammatory response by Th1 cells, and reduced release of pro-inflammatory cytokines by peritoneal macrophages may initially control the cytokine storm.</description><identifier>ISSN: 1567-5769</identifier><identifier>ISSN: 1878-1705</identifier><identifier>EISSN: 1878-1705</identifier><identifier>DOI: 10.1016/j.intimp.2024.112470</identifier><identifier>PMID: 38908085</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Acute Lung Injury (ALI) ; Acute Lung Injury - drug therapy ; Acute Lung Injury - immunology ; Animals ; Anti-inflammatory ; Anti-Inflammatory Agents - pharmacology ; Anti-Inflammatory Agents - therapeutic use ; B7-2 Antigen - metabolism ; Cells, Cultured ; Cytokine Release Syndrome - drug therapy ; Cytokine Release Syndrome - immunology ; Cytokines - metabolism ; Delayed-Type Hypersensitivity (DTH) ; Dendritic Cells - drug effects ; Dendritic Cells - immunology ; Disease Models, Animal ; Female ; Hsp90 ; HSP90 Heat-Shock Proteins - antagonists & inhibitors ; HSP90 Heat-Shock Proteins - metabolism ; Hypersensitivity, Delayed - drug therapy ; Hypersensitivity, Delayed - immunology ; Inflammation - drug therapy ; Inflammation - immunology ; Macrophages, Peritoneal - drug effects ; Macrophages, Peritoneal - immunology ; Macrophages, Peritoneal - metabolism ; Mice ; Mice, Inbred C57BL ; Spleen - drug effects ; Spleen - immunology ; Th1 Cells - drug effects ; Th1 Cells - immunology</subject><ispartof>International immunopharmacology, 2024-08, Vol.137, p.112470, Article 112470</ispartof><rights>2024</rights><rights>Copyright © 2024. Published by Elsevier B.V.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c241t-a841bf906dff5f7660ad8c15afa44ca17dc379d8bca8db7c1cf9608bcf6197593</cites><orcidid>0000-0003-0257-9207 ; 0009-0001-3444-2080 ; 0009-0000-7092-336X ; 0009-0006-0353-902X ; 0000-0002-2268-8761 ; 0000-0002-1810-5383</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.intimp.2024.112470$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38908085$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sim, Hyun Bo</creatorcontrib><creatorcontrib>Sang Son, Jun</creatorcontrib><creatorcontrib>Gupta, Sunil K.</creatorcontrib><creatorcontrib>Jeong, Seung-Hyun</creatorcontrib><creatorcontrib>Choi, Yu-Jeong</creatorcontrib><creatorcontrib>Han, Ji Yeon</creatorcontrib><creatorcontrib>Ramos, Sonny C.</creatorcontrib><creatorcontrib>Kim, Hyeongyeong</creatorcontrib><creatorcontrib>Park, Dae-Han</creatorcontrib><creatorcontrib>Yoo, Ho Jin</creatorcontrib><creatorcontrib>Yoo, Young Joo</creatorcontrib><creatorcontrib>Chang, Dong-Jo</creatorcontrib><creatorcontrib>Mun, Seul-Ki</creatorcontrib><creatorcontrib>Seo, Young Ho</creatorcontrib><creatorcontrib>Kim, Jong-Jin</creatorcontrib><title>Development of Hsp90 inhibitor to regulate cytokine storms in excessive delayed- and acute inflammation</title><title>International immunopharmacology</title><addtitle>Int Immunopharmacol</addtitle><description>•Excessive cytokine storms can be controlled through Hsp90.•Be01 has anti-inflammatory effects by decreasing surface molecules and cytokines in DCs and macrophages.•Inhibiting Hsp90 via Be01 highly decreased inflammation in vivo DTH and ALI models.
The surplus cytokines remaining after use in the early stages of the inflammatory response stimulate immune cells even after the response is over, causing a secondary inflammatory response and ultimately damaging the host, which is called a cytokine storm. Inhibiting heat shock protein 90 (Hsp90), which has recently been shown to play an important role in regulating inflammation in various cell types, may help control excessive inflammatory responses and cytokine storms.
We discovered an anti-inflammatory compound by measuring the inhibitory effect of CD86 expression on spleen DCs (sDCs) using the chemical compounds library of Hsp90 inhibitors. Subsequently, to select the hit compound, the production of cytokines and expression of surface molecules were measured on the bone marrow-derived DCs (BMDCs) and peritoneal macrophages. Then, we analyzed the response of antigen-specific Th1 cells. Finally, we confirmed the effect of the compound using acute lung injury (ALI) and delayed-type hypersensitivity (DTH) models.
We identified Be01 as the hit compound, which reduced CD86 expression the most in sDCs. Treatment with Be01 decreased the production of pro-inflammatory cytokines (IL-6, TNF-α, and IL-1β) in BMDC and peritoneal macrophages stimulated by LPS. Under the DTH model, Be01 treatment reduced ear swelling and pro-inflammatory cytokines in the spleen. Similarly, Be01 treatment in the ALI model decreased neutrophil infiltration and lower levels of secreted cytokines (IL-6, TNF-α).
Reduction of CD80 and CD86 expression on DCs by Be01 indicates reduced secondary inflammatory response by Th1 cells, and reduced release of pro-inflammatory cytokines by peritoneal macrophages may initially control the cytokine storm.</description><subject>Acute Lung Injury (ALI)</subject><subject>Acute Lung Injury - drug therapy</subject><subject>Acute Lung Injury - immunology</subject><subject>Animals</subject><subject>Anti-inflammatory</subject><subject>Anti-Inflammatory Agents - pharmacology</subject><subject>Anti-Inflammatory Agents - therapeutic use</subject><subject>B7-2 Antigen - metabolism</subject><subject>Cells, Cultured</subject><subject>Cytokine Release Syndrome - drug therapy</subject><subject>Cytokine Release Syndrome - immunology</subject><subject>Cytokines - metabolism</subject><subject>Delayed-Type Hypersensitivity (DTH)</subject><subject>Dendritic Cells - drug effects</subject><subject>Dendritic Cells - immunology</subject><subject>Disease Models, Animal</subject><subject>Female</subject><subject>Hsp90</subject><subject>HSP90 Heat-Shock Proteins - antagonists & inhibitors</subject><subject>HSP90 Heat-Shock Proteins - metabolism</subject><subject>Hypersensitivity, Delayed - drug therapy</subject><subject>Hypersensitivity, Delayed - immunology</subject><subject>Inflammation - drug therapy</subject><subject>Inflammation - immunology</subject><subject>Macrophages, Peritoneal - drug effects</subject><subject>Macrophages, Peritoneal - immunology</subject><subject>Macrophages, Peritoneal - metabolism</subject><subject>Mice</subject><subject>Mice, Inbred C57BL</subject><subject>Spleen - drug effects</subject><subject>Spleen - immunology</subject><subject>Th1 Cells - drug effects</subject><subject>Th1 Cells - immunology</subject><issn>1567-5769</issn><issn>1878-1705</issn><issn>1878-1705</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kE1PJCEQhsnGzarj_gNjOHrpEfoL-mJi_E5M9rKeCQ2Fy9gNLdCTnX8vk1aPniiop-oND0KnlKwpoe3FZm1dsuO0LklZrykta0Z-oCPKGS8oI81BrpuWFQ1ru0N0HOOGkPxe01_osOId4YQ3R-jlBrYw-GkEl7A3-CFOHcHW_bO9TT7g5HGAl3mQCbDaJf9qHeCYO2PMFIb_CmK0W8AaBrkDXWDpNJZqzrx1ZpDjKJP17gT9NHKI8PvjXKHnu9u_1w_F05_7x-urp0KVNU2F5DXtTUdabUxjWNsSqbmijTSyrpWkTKuKdZr3SnLdM0WV6VqSr6alHWu6aoXOl71T8G8zxCRGGxUMg3Tg5ygqwmjJq7IhGa0XVAUfYwAjpmBHGXaCErFXLDZiUSz2isWiOI-dfSTM_Qj6a-jTaQYuFwDyP7cWgojKglOgbQCVhPb2-4R3BDOQ0g</recordid><startdate>20240820</startdate><enddate>20240820</enddate><creator>Sim, Hyun Bo</creator><creator>Sang Son, Jun</creator><creator>Gupta, Sunil K.</creator><creator>Jeong, Seung-Hyun</creator><creator>Choi, Yu-Jeong</creator><creator>Han, Ji Yeon</creator><creator>Ramos, Sonny C.</creator><creator>Kim, Hyeongyeong</creator><creator>Park, Dae-Han</creator><creator>Yoo, Ho Jin</creator><creator>Yoo, Young Joo</creator><creator>Chang, Dong-Jo</creator><creator>Mun, Seul-Ki</creator><creator>Seo, Young Ho</creator><creator>Kim, Jong-Jin</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-0257-9207</orcidid><orcidid>https://orcid.org/0009-0001-3444-2080</orcidid><orcidid>https://orcid.org/0009-0000-7092-336X</orcidid><orcidid>https://orcid.org/0009-0006-0353-902X</orcidid><orcidid>https://orcid.org/0000-0002-2268-8761</orcidid><orcidid>https://orcid.org/0000-0002-1810-5383</orcidid></search><sort><creationdate>20240820</creationdate><title>Development of Hsp90 inhibitor to regulate cytokine storms in excessive delayed- and acute inflammation</title><author>Sim, Hyun Bo ; Sang Son, Jun ; Gupta, Sunil K. ; Jeong, Seung-Hyun ; Choi, Yu-Jeong ; Han, Ji Yeon ; Ramos, Sonny C. ; Kim, Hyeongyeong ; Park, Dae-Han ; Yoo, Ho Jin ; Yoo, Young Joo ; Chang, Dong-Jo ; Mun, Seul-Ki ; Seo, Young Ho ; Kim, Jong-Jin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c241t-a841bf906dff5f7660ad8c15afa44ca17dc379d8bca8db7c1cf9608bcf6197593</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Acute Lung Injury (ALI)</topic><topic>Acute Lung Injury - drug therapy</topic><topic>Acute Lung Injury - immunology</topic><topic>Animals</topic><topic>Anti-inflammatory</topic><topic>Anti-Inflammatory Agents - pharmacology</topic><topic>Anti-Inflammatory Agents - therapeutic use</topic><topic>B7-2 Antigen - metabolism</topic><topic>Cells, Cultured</topic><topic>Cytokine Release Syndrome - drug therapy</topic><topic>Cytokine Release Syndrome - immunology</topic><topic>Cytokines - metabolism</topic><topic>Delayed-Type Hypersensitivity (DTH)</topic><topic>Dendritic Cells - drug effects</topic><topic>Dendritic Cells - immunology</topic><topic>Disease Models, Animal</topic><topic>Female</topic><topic>Hsp90</topic><topic>HSP90 Heat-Shock Proteins - antagonists & inhibitors</topic><topic>HSP90 Heat-Shock Proteins - metabolism</topic><topic>Hypersensitivity, Delayed - drug therapy</topic><topic>Hypersensitivity, Delayed - immunology</topic><topic>Inflammation - drug therapy</topic><topic>Inflammation - immunology</topic><topic>Macrophages, Peritoneal - drug effects</topic><topic>Macrophages, Peritoneal - immunology</topic><topic>Macrophages, Peritoneal - metabolism</topic><topic>Mice</topic><topic>Mice, Inbred C57BL</topic><topic>Spleen - drug effects</topic><topic>Spleen - immunology</topic><topic>Th1 Cells - drug effects</topic><topic>Th1 Cells - immunology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sim, Hyun Bo</creatorcontrib><creatorcontrib>Sang Son, Jun</creatorcontrib><creatorcontrib>Gupta, Sunil K.</creatorcontrib><creatorcontrib>Jeong, Seung-Hyun</creatorcontrib><creatorcontrib>Choi, Yu-Jeong</creatorcontrib><creatorcontrib>Han, Ji Yeon</creatorcontrib><creatorcontrib>Ramos, Sonny C.</creatorcontrib><creatorcontrib>Kim, Hyeongyeong</creatorcontrib><creatorcontrib>Park, Dae-Han</creatorcontrib><creatorcontrib>Yoo, Ho Jin</creatorcontrib><creatorcontrib>Yoo, Young Joo</creatorcontrib><creatorcontrib>Chang, Dong-Jo</creatorcontrib><creatorcontrib>Mun, Seul-Ki</creatorcontrib><creatorcontrib>Seo, Young Ho</creatorcontrib><creatorcontrib>Kim, Jong-Jin</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>International immunopharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sim, Hyun Bo</au><au>Sang Son, Jun</au><au>Gupta, Sunil K.</au><au>Jeong, Seung-Hyun</au><au>Choi, Yu-Jeong</au><au>Han, Ji Yeon</au><au>Ramos, Sonny C.</au><au>Kim, Hyeongyeong</au><au>Park, Dae-Han</au><au>Yoo, Ho Jin</au><au>Yoo, Young Joo</au><au>Chang, Dong-Jo</au><au>Mun, Seul-Ki</au><au>Seo, Young Ho</au><au>Kim, Jong-Jin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Development of Hsp90 inhibitor to regulate cytokine storms in excessive delayed- and acute inflammation</atitle><jtitle>International immunopharmacology</jtitle><addtitle>Int Immunopharmacol</addtitle><date>2024-08-20</date><risdate>2024</risdate><volume>137</volume><spage>112470</spage><pages>112470-</pages><artnum>112470</artnum><issn>1567-5769</issn><issn>1878-1705</issn><eissn>1878-1705</eissn><abstract>•Excessive cytokine storms can be controlled through Hsp90.•Be01 has anti-inflammatory effects by decreasing surface molecules and cytokines in DCs and macrophages.•Inhibiting Hsp90 via Be01 highly decreased inflammation in vivo DTH and ALI models.
The surplus cytokines remaining after use in the early stages of the inflammatory response stimulate immune cells even after the response is over, causing a secondary inflammatory response and ultimately damaging the host, which is called a cytokine storm. Inhibiting heat shock protein 90 (Hsp90), which has recently been shown to play an important role in regulating inflammation in various cell types, may help control excessive inflammatory responses and cytokine storms.
We discovered an anti-inflammatory compound by measuring the inhibitory effect of CD86 expression on spleen DCs (sDCs) using the chemical compounds library of Hsp90 inhibitors. Subsequently, to select the hit compound, the production of cytokines and expression of surface molecules were measured on the bone marrow-derived DCs (BMDCs) and peritoneal macrophages. Then, we analyzed the response of antigen-specific Th1 cells. Finally, we confirmed the effect of the compound using acute lung injury (ALI) and delayed-type hypersensitivity (DTH) models.
We identified Be01 as the hit compound, which reduced CD86 expression the most in sDCs. Treatment with Be01 decreased the production of pro-inflammatory cytokines (IL-6, TNF-α, and IL-1β) in BMDC and peritoneal macrophages stimulated by LPS. Under the DTH model, Be01 treatment reduced ear swelling and pro-inflammatory cytokines in the spleen. Similarly, Be01 treatment in the ALI model decreased neutrophil infiltration and lower levels of secreted cytokines (IL-6, TNF-α).
Reduction of CD80 and CD86 expression on DCs by Be01 indicates reduced secondary inflammatory response by Th1 cells, and reduced release of pro-inflammatory cytokines by peritoneal macrophages may initially control the cytokine storm.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>38908085</pmid><doi>10.1016/j.intimp.2024.112470</doi><orcidid>https://orcid.org/0000-0003-0257-9207</orcidid><orcidid>https://orcid.org/0009-0001-3444-2080</orcidid><orcidid>https://orcid.org/0009-0000-7092-336X</orcidid><orcidid>https://orcid.org/0009-0006-0353-902X</orcidid><orcidid>https://orcid.org/0000-0002-2268-8761</orcidid><orcidid>https://orcid.org/0000-0002-1810-5383</orcidid></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1567-5769 |
ispartof | International immunopharmacology, 2024-08, Vol.137, p.112470, Article 112470 |
issn | 1567-5769 1878-1705 1878-1705 |
language | eng |
recordid | cdi_proquest_miscellaneous_3071283250 |
source | MEDLINE; ScienceDirect Journals (5 years ago - present) |
subjects | Acute Lung Injury (ALI) Acute Lung Injury - drug therapy Acute Lung Injury - immunology Animals Anti-inflammatory Anti-Inflammatory Agents - pharmacology Anti-Inflammatory Agents - therapeutic use B7-2 Antigen - metabolism Cells, Cultured Cytokine Release Syndrome - drug therapy Cytokine Release Syndrome - immunology Cytokines - metabolism Delayed-Type Hypersensitivity (DTH) Dendritic Cells - drug effects Dendritic Cells - immunology Disease Models, Animal Female Hsp90 HSP90 Heat-Shock Proteins - antagonists & inhibitors HSP90 Heat-Shock Proteins - metabolism Hypersensitivity, Delayed - drug therapy Hypersensitivity, Delayed - immunology Inflammation - drug therapy Inflammation - immunology Macrophages, Peritoneal - drug effects Macrophages, Peritoneal - immunology Macrophages, Peritoneal - metabolism Mice Mice, Inbred C57BL Spleen - drug effects Spleen - immunology Th1 Cells - drug effects Th1 Cells - immunology |
title | Development of Hsp90 inhibitor to regulate cytokine storms in excessive delayed- and acute inflammation |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T07%3A37%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Development%20of%20Hsp90%20inhibitor%20to%20regulate%20cytokine%20storms%20in%20excessive%20delayed-%20and%20acute%20inflammation&rft.jtitle=International%20immunopharmacology&rft.au=Sim,%20Hyun%20Bo&rft.date=2024-08-20&rft.volume=137&rft.spage=112470&rft.pages=112470-&rft.artnum=112470&rft.issn=1567-5769&rft.eissn=1878-1705&rft_id=info:doi/10.1016/j.intimp.2024.112470&rft_dat=%3Cproquest_cross%3E3071283250%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3071283250&rft_id=info:pmid/38908085&rft_els_id=S1567576924009913&rfr_iscdi=true |